Medidata talks launching the world’s first fully end-to-end DCT platform
Medidata’s Lisa Moneymaker breaks down the firm’s end-to-end DCT program and its benefits for patients and CROs
Medical Devices
Heart rate and respiration patterns measured digitally have the most potential for immediate use in clinical trials: Poll
Digital devices enable the measuring of biomarkers such as heart rate, blood sugar and even...
Angion’s ANG-3777 prior data, multitargeted MOA well-placed to tackle delayed graft function but faces uphill task in complex patient population
Angion Biomedica’s bid to treat delayed graft function (DGF) following kidney transplantation is strong with...
Brave new world: trialling VR to ease pain and stress
Virtual reality has shown the potential to help patients deal with pain and anxiety during...
MDIC report explores boosting patient engagement in clinical trials
The US Medical Device Innovation Consortium (MDIC) has published a report on how to improve...
ObvioHealth Q&A: connecting DCT dots with remote tech
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving at a matching pace. Clinical Trials Arena sat down with virtual research organisation (VRO) ObvioHealth...
Bionic Vision advances clinical programme with Australian government grant
Melbourne-based Australian medical technology start-up Bionic Vision Technologies (BVT) has announced that it is advancing next phase of development for its clinical programme after receiving a grant from the Australian Government.
InSilicoTrials: accelerating the uptake of simulation in clinical research
Italian start-up InSilicoTrials is taking advantage of three EU-funded projects to accelerate the uptake of its simulation technology in the development of new medical devices and drugs. What could this could mean for the future...
How medical-grade silicone can transform transdermal drug delivery
Delivering therapeutic drugs by applying substances to the skin is a practise that dates back thousands of years, but is has only been since the 1970s that we have better…
Future of Merck KGaA/Pfizer’s Bavencio at risk despite bladder trial success
The recent success of Pfizer and Merck KGaA’s Phase III JAVELIN Bladder 100 confirmatory study investigating Bavencio (avelumab) with best supportive care as the first-line maintenance treatment for patients with…
August’s top news stories
Biopharmaceutical firm Retrophin reported that the Phase III clinical trial of fosmetpantotenate failed to meet endpoints in pantothenate kinase-associated neurodegeneration (PKAN) patients; and MyoKardia has commenced dosing of patients in a Phase I trial of...
